Hatteras Venture Partners, based in Durham, N.C., recently closed its Hatteras Venture Partners VII (HVP VII) and Hatteras Opportunity Fund I, LP (HOF I), raising over $200 million from limited partners. This milestone coincided with the investment in its 100th portfolio company and marked the 25th year of the company’s operation. Notably, the firm focuses on building transformative human medicine companies that have a positive impact on patients and healthcare professionals.
The journey of Hatteras began in 2000 with the establishment of Hatteras Venture Partners I, LP, a seed-stage venture fund with $2.93 million in capital. Over the years, the company has evolved to manage more than $900 million in capital, specifically targeting seed- and early-stage companies in biotechnology, medtech, and healthtech sectors. Hatteras aims to invest in life sciences companies that drive innovation in healthcare and challenge the conventional norms.
Several success stories have emerged from Hatteras’s portfolio, including HistoSonics, Kymera Therapeutics, G1 Therapeutics, Jumo Health, Iris Healthcare, Asthmatx, Synthematix, among others. These companies have made significant strides in various areas such as targeted protein degradation, histotripsy for tissue destruction, health education, and end-of-life care planning. Their achievements have not only impacted the market but have also demonstrated the effectiveness of Hatteras’s investment strategy.
In a recent move, Hatteras announced the promotion of Lauren Flickinger and Ben Scruggs, Ph.D., as Partners, further strengthening its team. Ben Scruggs, with a focus on biopharmaceuticals and tools investments, has been instrumental in leading portfolio company Altis Biosystems. On the other hand, Lauren Flickinger, who joined Hatteras from Morgan Stanley, brings her expertise in health technology, playing a crucial role in managing the Pisgah Fund in Asheville, N.C. These promotions reflect Hatteras’s commitment to nurturing talent and driving future growth.
Looking ahead, Hatteras remains dedicated to fostering innovation in the healthcare industry and supporting groundbreaking ideas that have the potential to transform patient care. With a seasoned team of entrepreneurs and operators, the firm continues to explore new opportunities and expand its influence in the seed- and early-stage investing landscape. As Hatteras embarks on the next phase of its journey, the company’s vision and values are poised to shape the future of healthcare innovation.
Key Takeaways:
– Hatteras Venture Partners raised over $200 million in capital, signaling continued growth and investment in transformative healthcare companies.
– The firm’s success stories, including HistoSonics, Kymera Therapeutics, and G1 Therapeutics, highlight its commitment to driving innovation in biotechnology and healthcare.
– Promotions of key team members like Lauren Flickinger and Ben Scruggs underscore Hatteras’s focus on talent development and leadership succession.
– With a strong legacy of 25 years, Hatteras Venture Partners remains at the forefront of seed- and early-stage investing, driving positive change in the healthcare industry.
Read more on finance.yahoo.com